MedTrace Logo

SYL040012. Tolerance and Effect on Intraocular Pressure in Subjects With Intraocular Pressure (IOP) >= 21 mm Hg

NCT01227291 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2012-09-27

No results posted yet for this study

Summary

The aim of this study is to evaluate the tolerance and effect on unmedicated subjects with elevated IOP.

Conditions

Interventions

DRUG

SYL040012

SYL040012 ophthalmic drops, daily single dose administration

Sponsors & Collaborators

  • Sylentis, S.A.

    lead INDUSTRY

Principal Investigators

  • Javier Moreno, MD, PhD · Clinica Universidad de Navarra

  • Francisco Muñoz, MD, PhD · Hospital Universitario Ramon y Cajal

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2012-03-31
Completion
2012-09-30

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01227291 on ClinicalTrials.gov